Business Overview

Elevance Health, Inc. (NYSE: ELV), formerly Anthem, is one of the largest health benefits companies in the United States. It is a leading licensee of the Blue Cross Blue Shield brand in roughly 14 states (including large markets such as California, New York, and Ohio) and operates additional plans under the Wellpoint and other brands. The company provides medical, pharmacy, dental, vision, behavioral health, and disability coverage to tens of millions of members across commercial employer groups, individual (ACA marketplace) plans, and government-sponsored programs including Medicare Advantage, Medicaid managed care, and Medicare Part D.

Elevance earns money in two broad ways. Its Health Benefits business collects premiums from members, employers, and government payers in exchange for assuming medical risk, and also administers self-funded employer plans for an administrative fee (ASO/fee-based arrangements where the employer bears the claims cost). Its fast-growing Carelon segment is a health services platform that includes pharmacy benefit and specialty pharmacy services (CarelonRx), care delivery, behavioral health, and data-and-analytics offerings sold both to Elevance's own plans and to external clients. The company also reports a Corporate & Other category. The bulk of revenue is premium income from risk-based members, supplemented by product (pharmacy) revenue and administrative fees.

Financial Trends

Elevance is a high-revenue, relatively thin-margin business, which is typical for managed care. Most of the top line is premium revenue, and the single largest expense is benefit (medical) costs paid out to providers and pharmacies. The relationship between those two is captured by the benefit expense ratio (medical loss ratio, or MLR) — the share of premiums spent on care. Operating margins are driven less by pricing power than by disciplined underwriting, membership mix, and the ability to set premiums ahead of medical cost trend.

• Growth drivers: membership growth across Medicare Advantage and commercial lines, expansion of the Carelon services segment (especially CarelonRx pharmacy and care delivery), and acquisitions that add members or capabilities.
• Margin structure: the medical loss ratio plus the operating (SG&A) expense ratio largely determine profitability; small moves in the MLR can swing earnings meaningfully given the scale of premium revenue.
• Capital intensity: the business is balance-sheet heavy in regulated insurance reserves and goodwill/intangibles from acquisitions rather than physical capex; it carries substantial cash, investments, and reserves for unpaid claims.
• Cash generation: the model typically produces strong operating cash flow, which management has historically returned through dividends and share repurchases while also funding acquisitions and debt service.

The page above shows live SEC XBRL figures; treat this section as the qualitative shape of the model rather than a source of specific numbers.

What to Watch in the Filings

For a managed care company like Elevance, the most informative parts of the filings are the operating metrics and segment detail, not just the headline EPS. When reading the 10-K and 10-Q, focus on:

• Benefit expense ratio (medical loss ratio): the central profitability gauge. Watch the trend and management's commentary on medical cost trend, utilization, and whether premiums were priced adequately — particularly in Medicare and Medicaid.
• Membership counts by segment and funding type: risk-based vs. fee-based (self-funded) members, and growth or attrition in Medicare Advantage, Medicaid, commercial, and individual lines.
• Medicaid redeterminations: MD&A discussion of how post-pandemic eligibility redeterminations affect Medicaid enrollment and the acuity (cost level) of remaining members.
• Carelon segment results: revenue growth and operating gain from CarelonRx and care-delivery/services, plus how much is intercompany vs. external.
• Star Ratings and government rate notices: 8-K and MD&A references to CMS Medicare Advantage Star Ratings and annual rate updates, which directly affect future revenue and bonus payments.
• Reserves for unpaid claims (IBNR) and days in claims payable: indicators of reserve adequacy and claims timing.
• Capital actions and guidance: 8-Ks and earnings releases for buybacks, dividends, acquisitions, debt issuance, and any revisions to adjusted EPS guidance.

Key Risks

• Medical cost trend risk: if actual utilization and claims costs run higher than the assumptions baked into premiums, the medical loss ratio rises and earnings compress — a recurring risk highlighted by the industry, including in Medicare Advantage.
• Government program dependence: a large share of membership and revenue comes from Medicare Advantage, Medicaid, and ACA exchanges, exposing the company to CMS rate decisions, risk-adjustment rules, Star Ratings, and state Medicaid contract terms and reprocurements.
• Regulatory and political risk: the business is heavily regulated at federal and state levels; changes to the ACA, drug pricing rules, PBM regulation, minimum MLR rules, and Medicaid funding could materially affect results.
• Medicaid redetermination headwinds: enrollment losses and a sicker remaining risk pool from eligibility redeterminations can pressure margins if rates lag acuity.
• Concentration in the Blue Cross Blue Shield license: Elevance's right to use the BCBS brand in its states is governed by association rules and antitrust litigation/settlements affecting the broader Blue system.
• Integration and goodwill risk: growth through acquisitions creates large goodwill and intangible balances that could face impairment, plus integration execution risk.
• Competition: intense competition from UnitedHealth, CVS/Aetna, Cigna, Humana, and others on pricing, networks, and PBM/services capabilities.
• Cybersecurity and data privacy: the company handles sensitive health data at massive scale, making breaches and HIPAA-related liabilities a material operational risk.

Frequently Asked Questions